|

fulzerasib Clinical Trials

1 actively recruiting trial

Also known as: Platinum-Doublet, sintilimab

Pipeline

Phase 2: 1

Top Sponsors

  • Jianxing He1

Indications

  • Stage IB-IIIA NSCLC1
  • Resectable NSCLC1
  • KRAS G12C Mutation1
  • Lung Cancer1
  • Neoadjuvant Therapy1

Other1 trial

Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.